Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MGAM | O43451 | 4/20 | 0.48 |
| ▸ | SI | P14410 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621332 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL10032055 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL14747294 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL13756825 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL1296044 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL22251726 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL24872329 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL14856334 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL7098842 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL12352431 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-7795238-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | INDENIX PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188440-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | PNP, DUT, ATIC | LGALS8 3052/4885L3MBTL1 1891/4885MAPT 4678/4885 |
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | ATIC, SLC35B2, AASDHPPT | LGALS8 2553/4885L3MBTL1 1551/4885MAPT 4735/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | LGALS8 3368/4885L3MBTL1 2292/4885MAPT 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.